GI CANCERS

Phase 1 data show HER2 ADC trastuzumab rezetecan drives responses in advanced gastric/GEJ and colorectal cancers with manageable safety and low ILD.

Learn how ctDNA/MRD testing guides gastroesophageal cancer care—patient counseling, coverage hurdles, and what rising ctDNA means before scans.

New study signals ctDNA MRD clearance and 90% drops predict better gastroesophageal cancer outcomes, fueling calls for prospective trials.

Phase 1 expansion shows Varseta-M delivers notable response rates and manageable safety in heavily pretreated metastatic colorectal cancer, with FDA registrational planning underway.

FDA signals accelerated path for givastomig in CLDN18.2+ gastric/GEJ cancer, as phase 1b data show strong responses and tolerability.

ctDNA MRD monitoring offers new clues for stopping chemo safely in metastatic gastroesophageal cancer, linking molecular response to outcomes.

ctDNA MRD monitoring may augment scans and tumor markers, enabling earlier detection of gastroesophageal cancer recurrence, especially hard-to-image peritoneal relapse.

Academic centers are associated with greater biliary tract cancer surgery success while minority patients and nonacademic care face gaps, urging better resource allocation.

ctDNA MRD testing may spot hidden relapse and guide treatment holidays in metastatic gastroesophageal cancer, as deep ctDNA drops predict longer PFS.

Johns Hopkins Medicine develops a free immune atlas of pancreatic cancer trials, spotlighting blood-based signals to build stronger pancreatic cancer immunotherapy combinations.

Phase 2a data show oral namodenoson is well tolerated in heavily pretreated pancreatic cancer, with survival follow-up ongoing and FDA orphan status boosting promise.

During a live event, Hagen Kennecke, MD, discussed key trials shaping the treatment landscape of PNETs.

FDA grants tentative approval to PNT2003, a Lutathera radioequivalent PRRT for SSTR+ GEP-NETs, paving way for wider access by 2026.

FDA confirms first-line BRAF V600E mCRC gains: encorafenib plus cetuximab with FOLFOX or FOLFIRI improves PFS and OS.

FDA fast-tracks PLT012, a CD36 metabolic checkpoint antibody for liver cancer, as phase 1 trial tests safety and early efficacy.

Phase 3 BREAKWATER finds encorafenib+cetuximab+FOLFIRI improves PFS and response in first-line BRAF V600E metastatic colorectal cancer.

During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and PRRT.

FDA grants orphan drug designation to HCB101 for gastric cancer; early trials suggest safer CD47 checkpoint blockade with promising tumor control in advanced settings.

Nivolumab–ipilimumab extends survival in unresectable HCC, but US cost-effectiveness falls short; dosing changes or price cuts may shift value.

FDA approves Optune Pax, a wearable tumor treating fields device, to pair with GnP chemo in locally advanced pancreatic cancer, extending survival and delaying pain.

FDA fast-tracks irpagratinib for FGF19+ advanced liver cancer, with early trials showing strong response rates and ongoing combo study momentum.

Final MOUNTAINEER data show tucatinib plus trastuzumab delivers durable responses and manageable safety in HER2+ RAS wild-type metastatic colorectal cancer.

Interim DURIPANC data suggest rintatolimod plus durvalumab may extend survival and boost immune activity in post‑FOLFIRINOX metastatic pancreatic cancer.

Phase 3 interim data show anbenitamab plus chemo boosts survival and response in previously treated HER2-positive gastric cancer with manageable toxicity.

FDA fast-tracks pelareorep with bevacizumab and FOLFIRI for KRAS-mutant MSS metastatic colorectal cancer, after standout response and survival signals.